Markus Puhlmann - Feb 3, 2023 Form 3 Insider Report for Isoray, Inc. (CATX)

Role: Chief Medical Officer
Signature: /s/ Markus Puhlmann
Stock symbol: CATX
Transactions as of: Feb 3, 2023
Transactions value $: $0
Form type: 3
Date filed: 2/13/2023, 03:32 PM
Next filing: Dec 14, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	CATX	Common Stock						500K	Feb 3, 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	CATX	Stock Options (right to buy)							Feb 3, 2023	Common Stock	1.41M		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Fully vested as of 2/3/2023 due to acceleration as a result of merger of Viewpoint Molecular Targeting, Inc. into wholly owned subsidiary of Isoray, Inc. (the "Merger").
F2	Received in exchange for options to acquire 445,000 shares of common stock in Viewpoint Molecular Targeting, Inc. at an adjusted exercise price of $0.13 per share pursuant to the terms of the Merger.